Results 151 to 160 of about 106,865 (295)

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein. [PDF]

open access: yesEBioMedicine, 2022
Liu Z   +12 more
europepmc   +1 more source

Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co‐Infected With HIV

open access: yesTropical Medicine &International Health, EarlyView.
ABSTRACT Background HIV co‐infection affects host responses and pharmacokinetics (PK) of tuberculosis (TB) treatment. This study assessed the PK of first‐line anti‐TB drugs and clinical outcomes in patients with and without HIV co‐infection. Methods In this prospective observational study, 61 adults with sputum‐positive pulmonary TB, either confirmed ...
Aung Pyae Phyo   +14 more
wiley   +1 more source

Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis. [PDF]

open access: yesPlast Reconstr Surg, 2022
Liu H   +9 more
europepmc   +1 more source

Progression of Lipodystrophy (LD) with continued thymidine analogue usage: Long-term Follow-Up from a randomized clinical trial (The PIILR Study)

open access: yes, 2004
Purpose: During the 24-week PIILR study of protease inhibitor (PI) withdrawal, improved lipids and reduction in intraabdominal visceral fat was seen, however, there was also a loss of subcutaneous limb fat in patients with HIV-lipodystrophy (LD).
Cooper, D.A.   +8 more
core  

Microgravity‐induced changes in skeletal muscle and possible countermeasures: What we can learn from bed rest and human space studies

open access: yesExperimental Physiology, EarlyView.
Abstract Despite exercise countermeasures to sustain health and performance in spaceflight, complete maintenance of muscle mass and functions in microgravity is still not possible for most astronauts. The principal cause of the limited effectiveness of existing exercise countermeasures is the difficulty in achieving full loading forces in space.
Alessandra Bosutti   +6 more
wiley   +1 more source

Combined analysis of Two-Year Follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 nfection: OzCombo 1 and 2

open access: yes, 2003
Purpose: To compare inhibition of HIV replication, improvements in CD4+ T-cell counts, metabolic parameters, and body shape changes after 2 years of assigned therapy in OzCombo patients.
Cooper, D.A.   +38 more
core  

Glucocorticoids modulate drug transporter function in human fetal brain endothelial cells

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend P‐glycoprotein and breast cancer resistance protein are the most prominent drug transporters at the fetal blood–brain barrier. We isolated primary human fetal brain endothelial cells from early and mid‐gestation cerebral microvessels and exposed them to glucocorticoids cortisol and dexamethasone in vitro.
Nikola Ivanovski   +3 more
wiley   +1 more source

Clinical impact of double protease inhibitor boosting with Lopinavir/Ritonavir and Amprenavir as part of salvage antiretroviral therapy

open access: yes, 2003
Purpose: Double protease inhibitor (PI) boosting is being explored as a new strategy in salvage antiretroviral (ARV) therapy. However, if a negative drug interaction leads to decreased drug levels of either or both PIs, double PI boosting could lead to ...
Gough, K.   +10 more
core  

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy